Selected article for: "administration prior and live vaccine"
Author: Simon P. Jochems; Fernando Marcon; Beatriz F. Carniel; Mark Holloway; Elena Mitsi; Emma Smith; Jenna F. Gritzfeld; Carla Solórzano; Jesús Reiné; Sherin Pojar; Elissavet Nikolaou; Esther L. German; Angie Hyder-Wright; Helen Hill; Caz Hales; Wouter A.A de Steenhuijsen Piters; Debby Bogaert; Hugh Adler; Seher Zaidi; Victoria Connor; Jamie Rylance; Helder I. Nakaya; Daniela M. Ferreira
Title: Inflammation induced by influenza virus impairs innate control of human pneumococcal carriage
  • Document date: 2018_6_20
    • ID: 4fgz09cv_3
    Snippet: One safe way to simulate influenza infection in the nose is using Live Attenuated Influenza Vaccine 50 (LAIV), consisting of cold-adapted influenza viruses. LAIV has been shown to affect the 51 subsequent susceptibility to Spn and to lead to increased carriage density in murine models of 52 infection and in vaccinated children 12, 13 . In a randomised controlled trial, we showed that LAIV 53 administration prior to Spn challenge led to 50% increa.....
    Document: One safe way to simulate influenza infection in the nose is using Live Attenuated Influenza Vaccine 50 (LAIV), consisting of cold-adapted influenza viruses. LAIV has been shown to affect the 51 subsequent susceptibility to Spn and to lead to increased carriage density in murine models of 52 infection and in vaccinated children 12, 13 . In a randomised controlled trial, we showed that LAIV 53 administration prior to Spn challenge led to 50% increase in Spn acquisition by molecular methods 54 as well as 10-fold increase in nasopharyngeal bacterial load 14 .

    Search related documents:
    Co phrase search for related documents
    • bacterial load and influenza infection: 1, 2
    • bacterial load and influenza virus: 1, 2
    • bacterial load and molecular method: 1
    • bacterial load and murine model: 1, 2, 3, 4, 5, 6
    • carriage density and influenza infection: 1
    • carriage density and influenza virus: 1, 2
    • control trial and influenza infection: 1
    • control trial and influenza virus: 1
    • control trial and murine model: 1
    • control trial and randomised control trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • influenza infection and molecular method: 1
    • influenza infection and murine model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • influenza infection and nose influenza infection: 1
    • influenza infection and subsequent susceptibility: 1
    • influenza infection and vaccinated child: 1
    • influenza virus and murine model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • influenza virus and nose influenza infection: 1
    • influenza virus and Spn challenge: 1
    • influenza virus and subsequent susceptibility: 1